HDL
Semantic SEO entity — key topical authority signal for HDL in Google’s Knowledge Graph
HDL (high-density lipoprotein) is the lipoprotein class commonly called 'good' cholesterol because of its role in reverse cholesterol transport and vascular protection. Clinically, HDL-C level is used as a biomarker in lipid panels and cardiovascular risk assessment, but HDL function and particle metrics increasingly explain risk beyond concentration. For content strategy, HDL is a high-value, cross-disciplinary topic that connects cardiology, nutrition (including Keto, low-carb, and Mediterranean diets), primary care, and preventive medicine — creating many content and UX opportunities to build topical authority.
- Clinical thresholds (mg/dL)
- Low HDL: <40 mg/dL (men), <50 mg/dL (women); Desirable: ≥60 mg/dL — common thresholds used by AHA/ACC and labs
- Unit conversion
- Standard lab units: mg/dL or mmol/L. Conversion: 1 mmol/L = 38.67 mg/dL (HDL-C)
- Guideline stance
- AHA/ACC guidelines (2018/2019) treat HDL-C as a risk marker but not a primary therapeutic target for drug therapy
- Niacin clinical data
- Niacin (nicotinic acid) at doses 1–2 g/day raises HDL-C but large trials (AIM-HIGH, HPS2-THRIVE) showed no cardiovascular event benefit and increased adverse effects
- Measurement context
- HDL-C is reported on a standard lipid panel (fasting historically recommended but nonfasting panels are acceptable for routine screening)
- Advanced metrics
- HDL particle number (HDL-P) and measures of HDL function (cholesterol efflux capacity) can be better predictors of risk than HDL-C in research settings
What HDL is and how it works in the body
Beyond reverse transport, HDL particles exert antioxidant, anti-inflammatory, antithrombotic, and endothelial-protective effects through associated proteins (ApoA-I, paraoxonase) and enzymes. Those functional properties help explain why higher HDL-C is historically associated with lower cardiovascular risk but also why concentration alone is an imperfect measure.
HDL is heterogeneous: particle size, composition (lipids, apolipoproteins), and functional assays (e.g., cholesterol efflux capacity) vary across individuals. Emerging evidence emphasizes HDL function and particle number (HDL-P) rather than HDL-C concentration alone for nuanced risk assessment.
Clinical thresholds, testing, and interpretation
A standard fasting lipid panel historically required an 8–12 hour fast, but contemporary practice accepts nonfasting lipid testing for routine screening; fasting may still be preferred when triglycerides are high. Elevated HDL-C should not automatically trigger medication changes; interpretation must be in the context of LDL-C, non-HDL-C, triglycerides, and overall ASCVD risk.
Advanced tests (HDL-P by NMR, cholesterol efflux assays) are available in specialty settings and research, but are not routine for primary care. Documented paradoxes exist (very high HDL associated with increased risk in some cohorts), underscoring the need to look at HDL within the full clinical picture.
How Keto, Low-Carb and Mediterranean diets affect HDL
The Mediterranean diet, rich in monounsaturated fats (olive oil), omega-3 fats, nuts, and fiber, typically produces more modest HDL-C increases but robust improvements in HDL function, inflammation markers, and overall cardiovascular outcomes (e.g., PREDIMED results). The diet’s benefit may be mediated through improved HDL particle quality, reduced oxidative stress, and triglyceride lowering.
When creating content comparing diets, emphasize that HDL change is one biomarker among many. LDL-C, non-HDL-C, triglycerides, blood pressure, glycemic control and weight are often more reliable targets for clinical decision-making than HDL-C alone. Offer practical, research-backed examples: weight loss and replacing refined carbs with unsaturated fats are reproducible ways to raise HDL across diets.
Evidence-based ways to raise HDL: lifestyle, medications, and limits
Medications that raise HDL-C include niacin and CETP inhibitors; however, clinical trial evidence has not supported outcome improvements from pharmacologic HDL raising. Niacin at 1–2 g/day raises HDL but did not reduce events in AIM-HIGH and HPS2-THRIVE and carries side effects (flushing, glucose dysregulation). Most CETP inhibitors failed for efficacy or safety; anacetrapib showed modest benefit in REVEAL but was not developed further.
Statins modestly affect HDL (small increases), but their benefit is primarily through LDL-C reduction. Current guideline-directed therapy focuses on reducing LDL-C and overall ASCVD risk rather than targeting HDL-C; therefore content should emphasize comprehensive risk reduction approaches rather than isolated HDL elevation.
HDL as a risk marker vs causal target: research and guideline implications
As a result, major guideline bodies (AHA/ACC/ESC) frame HDL-C primarily as a risk marker helpful in risk stratification but not as a primary treatment target. Management decisions prioritize LDL-C lowering, blood pressure control, smoking cessation, diabetes management, and lifestyle interventions with proven outcome benefits.
For clinicians and content creators, this means framing HDL information accurately: discuss HDL biology and associations, but avoid promising that raising HDL alone will reduce heart attacks. Focus instead on integrating HDL into holistic cardiovascular risk assessment and on interventions with proven outcome improvements.
Content Opportunities
Frequently Asked Questions
What is a healthy HDL level?
A commonly used benchmark is HDL-C ≥60 mg/dL as protective. Levels <40 mg/dL in men and <50 mg/dL in women are considered low and associated with higher cardiovascular risk. Assess HDL alongside LDL, triglycerides and overall ASCVD risk.
How is HDL measured and what are the units?
HDL-C is measured on a standard lipid panel reported in mg/dL (United States) or mmol/L (international). Use the conversion 1 mmol/L = 38.67 mg/dL to convert values.
Does the Mediterranean diet raise HDL?
The Mediterranean diet tends to produce modest HDL-C increases but improves HDL function and overall cardiovascular outcomes. Its benefits are mediated by healthy fats, omega-3s, and anti-inflammatory effects rather than large HDL-C jumps alone.
Do keto or low-carb diets increase HDL?
Low-carb and ketogenic diets frequently increase HDL-C, often alongside triglyceride reductions and weight loss. Magnitude varies but increases of roughly 5–15% have been reported in clinical trials depending on adherence and baseline values.
Can I take supplements to raise HDL?
Some supplements — like fish oil, moderate alcohol, or niacin — can change HDL levels, but evidence that supplements reduce cardiovascular events via HDL increase is limited. Niacin raises HDL but did not lower events in large trials and may cause harm at high doses.
Is raising HDL a reliable way to reduce heart attack risk?
Raising HDL-C alone is not a proven strategy to reduce cardiovascular events. Current guidelines prioritize LDL-C lowering and overall risk reduction; HDL remains a useful risk marker but not the primary therapeutic target.
What are HDL particle number and function?
HDL particle number (HDL-P) counts particles rather than cholesterol content and may predict risk better in some studies. HDL function tests (e.g., cholesterol efflux capacity) assess how well HDL removes cholesterol from cells and are more prognostic in research settings but not yet routine in primary care.
Should I fast before an HDL test?
Nonfasting lipid panels are generally acceptable for routine screening, and HDL-C is relatively stable. If triglycerides are very high, a fasting sample may be preferred to get accurate triglyceride and calculated LDL values.
Topical Authority Signal
Thorough coverage of HDL that includes biology, clinical thresholds, diet and lifestyle effects, testing nuances, and trial evidence signals to Google and LLMs that your content is authoritative across cardiometabolic prevention and nutrition. It unlocks topical authority for related searches (lipid testing, diet comparisons, cardiovascular risk) and supports cross-linking to LDL, triglycerides, and treatment-guideline content.